4.6 Article

Use of High-Dose Nebulized Colistimethate in Patients with Colistin-Only Susceptible Acinetobacter baumannii VAP: Clinical, Pharmacokinetic and Microbiome Features

Related references

Note: Only part of the references are listed.
Article Infectious Diseases

Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia

Aikaterini Gkoufa et al.

Summary: This study assessed the pharmacokinetics of nebulised colistin methanesulfonate (CMS) for the treatment of ventilator-associated pneumonia (VAP) and found that nebulised CMS can achieve high concentrations of formed colistin in the epithelial lining fluid (ELF) while maintaining lower concentrations in plasma.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

Review Critical Care Medicine

Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials

Rui Tang et al.

Summary: Adjunctive inhaled antibiotic therapy can improve clinical cure rates and microbiological eradication in VAP patients, but does not reduce mortality. There is no increased risk of renal impairment with adjunctive inhaled antibiotics, but an increased risk of bronchospasm may be present.

JOURNAL OF CRITICAL CARE (2021)

Article Infectious Diseases

Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study

Jia-Yih Feng et al.

Summary: The study found that adjunctive nebulized colistin in critically ill patients with nosocomial pneumonia caused by colistin-susceptible CR-GNB was associated with a lower day 14 clinical failure rate, but no difference in the 14-day mortality rate was observed.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Review Microbiology

Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives

Yinggang Zhu et al.

Summary: Clinical evidence supports the benefits of nebulized colistimethate sodium (CMS) for treating lower respiratory tract infections caused by multidrug-resistant Gram-negative bacteria. However, the slower conversion of CMS to colistin compared to renal clearance may result in low plasma and lung colistin concentrations with intravenous administration, increasing the risk of treatment failure. Future research should focus on assessing the pharmacokinetics/pharmacodynamics of high-dose colistin nebulization, as well as comparing nebulized CMS to intravenous antibiotics in patients with ventilator-associated pneumonia caused by drug-resistant bacteria.

MICROORGANISMS (2021)

Article Critical Care Medicine

Staphylococcus aureus ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis

Gennaro De Pascale et al.

Summary: Our study showed that COVID-19 patients with SA-VAP had a higher incidence of late-onset, methicillin-resistant, and bacteremic infections compared to non-COVID-19 patients. While no significant differences were observed in ICU mortality, clinical cure, and microbiological eradication between the two groups, SAPS II score and initial inappropriate antimicrobial therapy were independently associated with ICU mortality. Additionally, lung microbiota composition was significantly different between COVID-19 and non-COVID-19 patients with SA-VAP, with certain bacteria being enriched in the COVID-19 group.

CRITICAL CARE (2021)

Article Biochemical Research Methods

Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients

Flavio De Maio et al.

BIOLOGICAL PROCEDURES ONLINE (2020)

Article Pharmacology & Pharmacy

Comparison of Salbutamol Delivery Efficiency for Jet versus Mesh Nebulizer Using Mice

Kyung Hwa Chang et al.

PHARMACEUTICS (2019)

Letter Biotechnology & Applied Microbiology

Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2

Evan Bolyen et al.

NATURE BIOTECHNOLOGY (2019)

Review Infectious Diseases

Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review

Aaron J. Heffernan et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)

Review Infectious Diseases

Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis

Konstantinos Z. Vardakas et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)

Review Infectious Diseases

Colistin: an update on the antibiotic of the 21st century

Silpak Biswas et al.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2012)

Article Critical Care Medicine

Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients

Zoe E. Athanassa et al.

INTENSIVE CARE MEDICINE (2012)

Review Critical Care Medicine

Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients

Argyris S. Michalopoulos et al.

ANNALS OF INTENSIVE CARE (2011)

Review Critical Care Medicine

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

Matthew E. Falagas et al.

CRITICAL CARE (2006)